A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Phase 3

Completed

• Conditions: Colo-rectal Cancer
• Interventions: Drug: Arfolitixorin; Drug: Leucovorin

• Registration Number: NCT03750786
• Lead Sponsor: Isofol Medical AB

Brief Summary

This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-11-19
• Study First Submitted QC: 2018-11-20
• Study First Posted: 2018-11-23
• Study Start: 2018-12-18
• Primary Completion: 2022-11-18
• Study Completion: 2022-11-18
• Results First Submitted: 2023-08-18
• Status Verified: 2023-10
• Results First Submitted QC: 2023-10-19
• Last Update Submitted: 2023-10-19
• Results First Posted: 2023-10-26
• Last Update Posted: 2023-10-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 490

Inclusion Criteria

1. Colorectal adenocarcinoma verified by biopsy.
2. Availability of biopsy material, from the primary tumor or metastasis, allowing for analysis of tumor gene expression.
3. Non-resectable metastatic CRC planned for first line therapy with 5-FU, Leucovorin, oxaliplatin, and bevacizumab.
4. Evaluable disease with at least one measurable lesion of metastatic disease (≥10 mm in longest diameter on axial image on CT-scan or alternatively MRI with <5 mm reconstruction interval) or lymph node (≥ 15 mm in shortest axis when assessed by CT) obtained within 28 days of randomization.
5. Life expectancy of more than 4 months.
6. ECOG performance status 0 or 1.
7. Hemoglobin (Hb) > 80 g/L, Absolute neutrophil count (ANC) > 1.5x10E9/L. Thrombocytes > 100x10E9/L.
8. Creatinine clearance > 50 mL/min, Total bilirubin < 1.5 x ULN, AST and ALT < 3 x ULN (and < 5 x ULN in case of liver metastases).
9. Male or female ≥18 years of age.
10. Female patients of childbearing potential must have a negative urine pregnancy test and use adequate contraceptive measures . Male patients must use adequate contraceptive measures .
11. Voluntarily signed informed consent before performance of any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion Criteria

1. Malignant tumors other than colorectal adenocarcinomas (current or within the previous five years), with the exception for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix.
2. Less than 6 months between randomization and completion of the last anti-cancer treatment (chemotherapy/radiotherapy/immunotherapy, etc.). (NB: Rectal cancer treatment shorter than 8 weeks of chemo/radiation therapy is allowed.)
3. Confirmation of progressive disease within 6 months after completion of prior adjuvant anti-cancer treatment.
4. Indication for any metastatic Colo-rectal Cancer (mCRC) surgery or anti-cancer treatment other than study treatment.
5. Prior treatment with arfolitixorin.
6. Indication for treatment with a 5-FU analogue, or 5-FU for a condition other than mCRC.
7. Known Dihydropyrimidine Dehydrogenase Deficiency (DPD) deficiency.
8. Known or suspected central nervous system (CNS) metastases.
9. Unresolved bowel obstruction, uncontrolled Crohn's disease, or ulcerative colitis.
10. History of cardiac disease with a New York Heart Association Class II or greater, congestive heart failure, myocardial infarction, or unstable angina at any time during the 6 months prior to randomization, or serious arrhythmias requiring medication for treatment.
11. Current CTCAE ≥ grade 3 diarrhea.
12. Current chronic infection or uncontrolled serious illness causing immunodeficiency.
13. Known or suspected hypersensitivity or intolerance to arfolitixorin, LV, 5-FU, oxaliplatin, or bevacizumab.
14. Breastfeeding patients.
15. Patient who received investigational drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug, prior to randomization.
16. Patient with serious medical or psychiatric illness likely to interfere with participation in this clinical study.
17. Ongoing drug or alcohol abuse, as deemed by the Investigator.
18. Any condition that, in the opinion of the Investigator, could compromise the patient's safety or adherence to the study protocol.
19. Involvement, or related to people involved in the planning or conduct of the study (applies to both Isofol Medical AB (publ) staff and staff at the study site)
20. Surgery (excluding previous diagnostic biopsy) in the 28-day period before randomization

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	Arfolitixorin	ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
Group B	Leucovorin	mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab

Primary Outcome Measures

Name	Time	Method
Overall Response Rate	Until disease progression, an average of ten months	Best ORR, defined as the best response recorded from the start of the study treatment until the end of treatment.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival	Until disease progression, an average of ten months	PFS, defined as the time from randomization to first occurrence of tumor progression based on CT-scans/MRIs.
Duration of Response	Until disease progression, an average of ten months	The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

Trial Locations

Locations (94)

840-24 - Banner Gateway Medical Center; 🇺🇸 Gilbert, Arizona, United States

840-15 - University of Southern California; 🇺🇸 Los Angeles, California, United States

840-01 - HOAG Memorial Hospital; 🇺🇸 Newport Beach, California, United States

840-13 - UCH-MHS d/b/a Memorial Health System; 🇺🇸 Colorado Springs, Colorado, United States

840-34 - Banner MD Anderson Cancer Center; 🇺🇸 Greeley, Colorado, United States

840-32 - University of Miami; 🇺🇸 Miami, Florida, United States

840-08 - Pinellas Hematology Oncology; 🇺🇸 Saint Petersburg, Florida, United States

840-30 - Joliet Oncology-Hematology Associates; 🇺🇸 Joliet, Illinois, United States

840-06 - Cancer Center of Kansas; 🇺🇸 Wichita, Kansas, United States

840-29 - Ashland-Bellefonte Cancer Center; 🇺🇸 Ashland, Kentucky, United States

Scroll for more (84 remaining)